Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/59194

Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting beta-amyloid, tau, and cholinesterase pathologies
Di Pietro, O.; Pérez-Areales, F. Javier; Juárez-Jiménez, Jordi; Espargaró Colomé, Alba; Clos Guillén, M. Victòria; Pérez Fernández, Belén; Lavilla Grífols, Rodolfo; Sabaté Lagunas, Raimon; Luque Garriga, F. Xavier; Muñoz-Torrero López-Ibarra, Diego
Universitat de Barcelona
Optimization of an essentially inactive 3,4-dihydro-2H-pyrano[3,2-c]quinoline carboxylic ester derivative as acetylcholinesterase (AChE) peripheral anionic site (PAS)-binding motif by double O → NH bioisosteric replacement, combined with molecular hybridization with the AChE catalytic anionic site (CAS) inhibitor 6-chlorotacrine and molecular dynamics-driven optimization of the length of the linker has resulted in the development of the trimethylene-linked 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridine
6-chlorotacrine hybrid 5a as a picomolar inhibitor of human AChE (hAChE). The tetra-, penta-, and octamethylene-linked homologues 5b
d have been also synthesized for comparison purposes, and found to retain the nanomolar hAChE inhibitory potency of the parent 6-chlorotacrine. Further biological profiling of hybrids 5a
d has shown that they are also potent inhibitors of human butyrylcholinesterase and moderately potent Aβ42 and tau anti-aggregating agents, with IC50 values in the submicromolar and low micromolar range, respectively. Also, in vitro studies using an artificial membrane model have predicted a good brain permeability for hybrids 5a
d, and hence, their ability to reach their targets in the central nervous system. The multitarget profile of the novel hybrids makes them promising leads for developing anti-Alzheimer drug candidates with more balanced biological activities.
Disseny de medicaments
Inhibidors enzimàtics
Malaltia d'Alzheimer
Pèptids
Proteïnes
Drug design
Enzyme inhibitors
Alzheimer's disease
Peptides
Proteins
(c) Elsevier Masson SAS, 2014
Artículo
info:eu-repo/semantics/acceptedVersion
Elsevier Masson SAS
         

Mostrar el registro completo del ítem

Documentos relacionados

Otros documentos del mismo autor/a

Di Pietro, O.; Pérez-Areales, F. Javier; Juárez-Jiménez, Jordi; Espargaró Colomé, Alba; Clos Guillén, M. Victòria; Pérez Fernández, Belén; Lavilla Grífols, Rodolfo; Sabaté Lagunas, Raimon; Luque Garriga, F. Xavier; Muñoz-Torrero López-Ibarra, Diego
Di Pietro, O.; Pérez-Areales, F. Javier; Juárez-Jiménez, Jordi; Espargaró Colomé, Alba; Clos Guillén, M. Victòria; Pérez Fernández, Belén; Lavilla Grífols, Rodolfo; Sabaté Lagunas, Raimon; Luque Garriga, F. Xavier; Muñoz-Torrero López-Ibarra, Diego
Pérez-Areales, F. Javier; Di Pietro, O.; Espargaró Colomé, Alba; Vallverdú i Queralt, Anna; Galdeano Cantador, Carlos; Ragusa, Ilaria M.; Viayna, Elisabet; Guillou, C.; Clos Guillén, M. Victòria; Pérez Fernández, Belén; Sabaté Lagunas, Raimon; Lamuela Raventós, Rosa Ma.; Luque Garriga, F. Xavier; Muñoz-Torrero López-Ibarra, Diego
Pérez-Areales, F. Javier; Di Pietro, O.; Espargaró Colomé, Alba; Vallverdú i Queralt, Anna; Galdeano Cantador, Carlos; Ragusa, Ilaria M.; Viayna, Elisabet; Guillou, C.; Clos Guillén, M. Victòria; Pérez Fernández, Belén; Sabaté Lagunas, Raimon; Lamuela Raventós, Rosa Ma.; Luque Garriga, F. Xavier; Muñoz-Torrero López-Ibarra, Diego
Pérez-Areales, F. Javier; Di Pietro, O.; Espargaró Colomé, Alba; Vallverdú i Queralt, Anna; Galdeano Cantador, Carlos; Ragusa, Ilaria M.; Viayna, E.; Guillou, C.; Clos Guillén, M. Victòria; Pérez Fernández, Belén; Sabaté Lagunas, Raimon; Lamuela Raventós, Rosa Ma.; Luque Garriga, F. Xavier; Muñoz-Torrero López-Ibarra, Diego